Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Net Cash Flow (2022 - 2025)

Entrada Therapeutics has reported Net Cash Flow over the past 4 years, most recently at -$2.9 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$2.9 million for Q4 2025, down 112.49% from a year ago — trailing twelve months through Dec 2025 was -$10.8 million (down 132.18% YoY), and the annual figure for FY2025 was -$10.8 million, down 132.18%.
  • Net Cash Flow for Q4 2025 was -$2.9 million at Entrada Therapeutics, down from $20.8 million in the prior quarter.
  • Over the last five years, Net Cash Flow for TRDA hit a ceiling of $182.5 million in Q1 2023 and a floor of -$202.5 million in Q1 2022.
  • Median Net Cash Flow over the past 4 years was -$1.0 million (2024), compared with a mean of -$12.3 million.
  • Biggest five-year swings in Net Cash Flow: surged 292.79% in 2023 and later plummeted 4101.68% in 2025.
  • Entrada Therapeutics' Net Cash Flow stood at -$8.2 million in 2022, then surged by 292.79% to $15.7 million in 2023, then skyrocketed by 47.34% to $23.2 million in 2024, then plummeted by 112.49% to -$2.9 million in 2025.
  • The last three reported values for Net Cash Flow were -$2.9 million (Q4 2025), $20.8 million (Q3 2025), and $4.6 million (Q2 2025) per Business Quant data.